NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
15 trialsNCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed
NCT05303090 2025-02-27
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
Fudan University
Phase 1 Completed
NCT03006926 2023-12-13
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1 Completed
NCT00121719 2023-06-22
An Open Label Dose Escalation Study Of E7080
Eisai Inc.
Phase 1 Completed
NCT01268293 2023-06-22
A Study of E7080 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT02788708 2022-09-19
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02935309 2022-05-31
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03009292 2021-09-28
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT03006887 2021-05-20
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT02578316 2017-06-20
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Eisai Inc.
Phase 1 Completed
NCT00280397 2016-10-07
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00121680 2015-12-11
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Eisai Inc.
Phase 1 Completed
NCT01240408 2015-03-04
E7080 Food Effect Study in Healthy Subjects
Eisai Inc.
Phase 1 Completed